SERUM/PLASMA MicroRNAs AND USES THEREOF

ABSTRACT

This invention provides a combination of microRNAs for evaluating the physiological and/or pathological condition of a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of a subject; and a method for evaluating the physiological and/or pathological condition of a subject, wherein the method includes determining all detectable microRNAs stably existing in the serum/plasma of a subject; and a kit for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system, prediction of complications occurrence and malignant diseases relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy as well as forensic authentication and prohibited drug inspection and the like, possessing a number of advantages such as extensive detection spectrum, high sensitivity, low cost, convenience for sampling, ease for sample preservation, etc. The said method can be widely used in work related to general survey of diseases and so on, improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, significantly increasing the clinical detection rate of diseases, all of which make it become an effective means for diagnosing diseases in an early phase.

REFERENCE OF RELATED APPLICATIONS

The present application is a divisional application of U.S. application Ser. No. 12/302,196 titled SERUM/PLASMA MICRORNAS AND USES THEREOF, which was filed on Nov. 24, 2008, and the entire contents of which are incorporated by reference herein.

SUBMISSION OF SEQUENCE LISTING

The Sequence Listing associated with this application is filed in electronic format via EFS-Web and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is Sequence_Listing_15454_00029. The size of the text file is 84 KB, and the text file was created on Dec. 30, 2013.

TECHNICAL FIELD

The present invention relates to microRNAs and uses thereof, more specifically, to serum/plasma microRNAs and the uses of serum/plasma microRNAs for diagnosis and differential diagnosis of diseases, prediction of complication occurrence and malignant disease relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy, forensic authentication and prohibited drug inspection and the like.

BACKGROUND ART

To locate and precisely detect disease markers has already been the important precondition for the diagnosis and treatment of various clinical diseases including various tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system. Although more and more disease markers have been found and utilized in general survey and diagnosis of clinical diseases as well as monitoring and controlling of therapeutic effects, their clinical application effects are obviously insufficient. For instance, tumor marker, e.g. alphafetoprotein, lactic dehydrogenase and carcinoembryonic antigen have been widely used in clinic. But these disease markers are far from meeting the needs of early diagnosis for cancer for the following two main reasons: (1) the sensitivity and specificity for the above-mentioned disease markers are relatively low, thus their detection results cannot be used as a diagnostic indicator of disease; (2) the early diagnosis rate of disease shall be positively correlative with the therapeutic effects. However, it is difficult for any of the aforesaid disease markers to meet such requirements for early diagnosis. Take cancer for example, the specificity of tumor differentiation is too high, the integrated sensitivity of tumor is relatively low, the samples sent to be detected are difficult to be repeatedly taken and the conditions to meet the preservation requirements for samples are too exacting, meanwhile, the cost is very high, thus under existing technology the spreading and use of the tumor markers available are hard to realize. The inherent defects of some traditional medical means such as biopsy, for example, incorrect material-extraction position, the inadequacy of sample materials for histocytes and human inexperience, etc., will all lead to misdiagnosis. Although other techniques such as imaging technique have been widely used for examination and diagnosis of diseases, there exists considerable limitation on the determination for disease degree. Consequently, it is very necessary to find out a maker for disease detection which is novel, sensitive and convenient to use and can also overcome the defects of existing markers as mentioned above.

MicroRNAs are defined as a kind of non-coding single-stranded small RNA moleculars of approximately from 19 to 23 nucleotides in length. They are highly conservative in evolution; and are closely related to many normal physiological activities of animals such as development process, tissue differentiation, cell apoptosis and energy metabolism; in addition, bear close relation with the occurrence and development of many diseases. Recent studies show that the expression levels of several microRNAs in chronic lymphocytic leukemia and Burkitt lymphoma are on average down-regulated to various extents; and that by analyzing and comparing the expressions of microRNAs in tissues of human lung cancer and human breast cancer, the expression levels of several tissue specific microRNAs have changed relative to normal tissues. Some studies demonstrate that microRNAs affect the occurrence and development of cardio-cerebrovascular diseases such as myocardial hypertrophy, heart failure, atherosclerosis, and are closely relative to metabolic diseases such as Diabetes II. These experimental results indicate that there exists inevitable connection between the expression and specificity changes of microRNAs and the occurrence and development of diseases.

For the unimaginable important role microRNAs played in the regulation of expression after gene transcription, microRNAs have some associations with diseases. First of all, the changes of microRNAs may be the cause of diseases. This is because both the inhibitor and the promoter of diseases may be target sites for microRNAs. If the expression of microRNA itself is disturbed, e.g., the expression level of microRNA which is originally to inhibit disease promoters decreases or the expression level of microRNA which is to inhibit disease inhibitor increases, its end results will both lead to changes in the expression of downstream genes and the overall disorder of some pathways, further inducing the occurrence of diseases. Secondly, the changes of microRNAs may also result from diseases. This is because, when a kind of disease such as cancer occurs, it will lead to the loss of chromosome segments, gene mutation or rapid amplification of chromosome segments; moreover, if the microRNAs happen to locate in the changing segment, then their expression level will extremely significantly change. Therefore, in theory, microRNAs can be completely regarded as a kind of new disease markers, the specificity changes of which inevitably correlate with the occurrence and development of diseases. Meanwhile, microRNA can also be used as a potential drug target, and it may greatly alleviate the occurrence and development of diseases by inhibiting the up-regulated microRNAs and overexpressedly down-regulated microRNAs in the course of a disease.

The inventor has carried out the research in the relevant fields of using microRNAs as disease markers, for instance, choosing colonic carcinoma which ranks forth in the incidence of malignant tumor as the research object. The research suggests that, during the process of colon benign polyps developing into malignant tumor, some microRNAs exhibit specificity changes, thereby a more sensitive and accurate method for the early diagnosis of colonic carcinoma having been set up through detecting the specific changes in microRNAs. However, since the sampling for tissue specimen is not easy, the wide application of this method in clinics is limited.

DETAILED DESCRIPTION OF THE INVENTION

The inventor focuses the research on the blood which is relatively easy to obtain and even can be collected via routine physical examination. Blood will circulate to all tissues in body and convey nutrients to cells whilst scavenging waste materials; therefore, blood is able to reflect the physiological pathology of the whole organism and its detection results is an indicator of human health. It is known that in serum/plasma there are many kinds of proteins such as total protein, albumin and globulin, many kinds of lipids such as HDL cholesterol and triglycerides, many kinds of carbohydrates, pigments, electrolytes, inorganic salts, and many kinds of enzymes such as amylase, alkaline phosphatase, acid phosphatase, cholinesterase and aldolase; moreover, there also exist many kinds of signaling molecules such as cytokines and hormone from tissues and organs in whole body. Currently, disease diagnosis is only limited to the above-mentioned biochemical indexes in serum/plasma, and no report is available regarding microRNAs in serum/plasma. It traditionally believed that there is no microRNA in serum/plasma, and that, if any, it will be rapidly degraded by RNase into small molecule segments and hence cannot be detected. However, microRNAs, consisting of from 19 to 23 nucleotides, possess specificity and relative stability in structure and hence are very likely present in serum/plasma. Meanwhile, since microRNAs are a new type of disease markers, it is anticipated that by studying whether or not microRNAs are present in serum/plasma, whether or not they can be detected and the connection between microRNAs and diseases, a new technology is established for the early disease diagnosis, disease identification as well as monitoring and controlling of course of diseases, prediction of malignant disease relapse and prognosis and complication occurrence, assessment of drug efficacy, guide of medication, individualized treatment, screening of active ingredients of Chinese Traditional Medicines, population taxonomy, etc., by use of the microRNAs stably existing in serum/plasma as well as their specificity changes.

The present invention provides a combination of microRNAs for evaluating physiological and/or pathological condition in a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of the subject.

The present invention further provides a method for evaluating physiological and/or pathological condition in a subject, wherein the method comprises determining all detectable microRNAs stably existing in the serum/plasma of the subject.

In the above-mentioned combination or method, all detectable microRNAs stably existing in serum/plasma of a subject may be all mature microRNAs in human serum/plasma, specifically include let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-1, miR-100, miR-101, miR-103, miR-105, miR-106a, miR-106b, miR-107, miR-10a, miR-10b, miR-122a, miR-124a, miR-125a, miR-125b, miR-126, miR-126*, miR-127, miR-128a, miR-128b, miR-129, miR-130a, miR-130b, miR-132, miR-133a, miR-133b, miR-134, miR-135a, miR-135b, miR-136, miR-137, miR-138, miR-139, miR-140, miR-141, miR-142-3p, miR-142-5p, miR-143, miR-144, miR-145, miR-146a, miR-146b, miR-147, miR-148a, miR-148b, miR-149, miR-150, miR-151, miR-152, miR-153, miR-154, miR-154*, miR-155, miR-15a, miR-15b, miR-16, miR-17-3p, miR-17-5p, miR-181a, miR-181b, miR-181c, miR-181d, miR-182, miR-182*, miR-183, miR-184, miR-185, miR-186, miR-187, miR-188, miR-189, miR-18a, miR-18a*, miR-18b, miR-190, miR-191, miR-191*, miR-192, miR-193a, miR-193b, miR-194, miR-195, miR-196a, miR-196b, miR-197, miR-198, miR-199a, miR-199a*, miR-199b, miR-19a, miR-19b, miR-200a, miR-200a*, miR-200b, miR-200c, miR-202, miR-202*, miR-203, miR-204, miR-205, miR-206, miR-208, miR-20a, miR-20b, miR-21, miR-210, miR-211, miR-212, miR-213, miR-214, miR-215, miR-216, miR-217, miR-218, miR-219, miR-22, miR-220, miR-221, miR-222, miR-223, miR-224, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-27a, miR-27b, miR-28, miR-296, miR-299-3p, miR-299-5p, miR-29a, miR-29b, miR-29c, miR-301, miR-302a, miR-302a*, miR-302b, miR-302b*, miR-302c, miR-302c*, miR-302d, miR-30a-3p, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-30e-5p, miR-31, miR-32, miR-320, miR-323, miR-324-3p, miR-324-5p, miR-325, miR-326, miR-328, miR-329, miR-33, miR-330, miR-331, miR-335, miR-337, miR-338, miR-339, miR-33b, miR-340, miR-342, miR-345, miR-346, miR-34a, miR-34b, miR-34c, miR-361, miR-362, miR-363, miR-363*, miR-365, miR-367, miR-368, miR-369-3p, miR-369-5p, miR-370, miR-371, miR-372, miR-373, miR-373*, miR-374, miR-375, miR-376a, miR-376a*, miR-376b, miR-377, miR-378, miR-379, miR-380-3p, miR-380-5p, miR-381, miR-382, miR-383, miR-384, miR-409-3p, miR-409-5p, miR-410, miR-411, miR-412, miR-421, miR-422a, miR-422b, miR-423, miR-424, miR-425, miR-425-5p, miR-429, miR-431, miR-432, miR-432*, miR-433, miR-448, miR-449, miR-450, miR-451, miR-452, miR-452*, miR-453, miR-455, miR-483, miR-484, miR-485-3p, miR-485-5p, miR-486, miR-487a, miR-487b, miR-488, miR-489, miR-490, miR-491, miR-492, miR-493, miR-493-3p, miR-494, miR-495, miR-496, miR-497, miR-498, miR-499, miR-500, miR-501, miR-502, miR-503, miR-504, miR-505, miR-506, miR-507, miR-508, miR-509, miR-510, miR-511, miR-512-3p, miR-512-5p, miR-513, miR-514, miR-515-3p, miR-515-5p, miR-516-3p, miR-516-5p, miR-517*, miR-517a, miR-517b, miR-517c, miR-518a, miR-518a-2*, miR-518b, miR-518c, miR-518c*, miR-518d, miR-518e, miR-518f, miR-518f*, miR-519a, miR-519b, miR-519c, miR-519d, miR-519e, miR-519e*, miR-520a, miR-520a*, miR-520b, miR-520c, miR-520d, miR-520d*, miR-520e, miR-520f, miR-520g, miR-520h, miR-521, miR-522, miR-523, miR-524, miR-524*, miR-525, miR-525*, miR-526a, miR-526b, miR-526b*, miR-526c, miR-527, miR-532, miR-542-3p, miR-542-5p, miR-544, miR-545, miR-548a, miR-548b, miR-548c, miR-548th miR-549, miR-550, miR-551a, miR-552, miR-553, miR-554, miR-555, miR-556, miR-557, miR-558, miR-559, miR-560, miR-561, miR-562, miR-563, miR-564, miR-565, miR-566, miR-567, miR-568, miR-569, miR-570, miR-571, miR-572, miR-573, miR-574, miR-575, miR-576, miR-577, miR-578, miR-579, miR-580, miR-581, miR-582, miR-583, miR-584, miR-585, miR-586, miR-587, miR-588, miR-589, miR-590, miR-591, miR-592, miR-593, miR-594, miR-595, miR-596, miR-597, miR-598, miR-599, miR-600, miR-601, miR-602, miR-603, miR-604, miR-605, miR-606, miR-607, miR-608, miR-609, miR-610, miR-611, miR-612, miR-613, miR-614, miR-615, miR-616, miR-617, miR-618, miR-619, miR-620, miR-621, miR-622, miR-623, miR-624, miR-625, miR-626, miR-627, miR-628, miR-629, miR-630, miR-631, miR-632, miR-633, miR-634, miR-635, miR-636, miR-637, miR-638, miR-639, miR-640, miR-641, miR-642, miR-643, miR-644, miR-645, miR-646, miR-647, miR-648, miR-649, miR-650, miR-651, miR-652, miR-653, miR-654, miR-655, miR-656, miR-657, miR-658, miR-659, miR-660, miR-661, miR-662, miR-663, miR-7, miR-9, miR-9*, miR-92, miR-93, miR-95, miR-96, miR-98, miR-99 and miR-99b.

The aforesaid method for determining all detectable microRNAs stably existing in serum/plasma of a subject is one or more selected from the group consisting of RT-PCR method, Real-time PCR method, Northern blotting method, RNase protection assay, Solexa sequencing technology and biochip method.

The aforesaid RT-PCR method includes the following steps:

(1) extracting the total RNA from the serum/plasma of a subject and obtaining cDNA samples by RNA reverse transcription reaction; or collecting serum/plasma samples from the subject and conducting reverse transcription reaction with serum/plasma being a buffer so as to prepare cDNA samples;

(2) designing a primer by use of microRNAs and conducting PCR reaction;

(3) conducting agarose gel electrophoresis of PCR products;

(4) observing agarose gel under ultraviolet lamp after EB staining.

The aforesaid real-time PCR method includes the following steps:

(1) extracting the total RNA from the serum/plasma of a subject and obtaining cDNA samples by RNA reverse transcription reaction; or collecting serum/plasma samples from the subject and conducting reverse transcription reaction with serum/plasma being a buffer so as to prepare cDNA samples;

(2) designing a primer by use of microRNAs;

(3) adding a fluorescent probe to conduct PCR reaction;

(4) detecting and comparing the variation in levels of microRNAs in the serum/plasma relative to those of microRNAs in normal serum/plasma.

The present invention further provides a kit for evaluating physiological and/or pathological condition of a subject, wherein the kit comprises the tools for determining all detectable microRNAs stably existing in the serum/plasma of the subject. The kit may comprises the primers of all mature microRNAs in human serum/plasma, specifically comprises the primers of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-1, miR-100, miR-101, miR-103, miR-105, miR-106a, miR-106b, miR-107, miR-10a, miR-10b, miR-122a, miR-124a, miR-125a, miR-125b, miR-126, miR-126*, miR-127, miR-128a, miR-128b, miR-129, miR-130a, miR-130b, miR-132, miR-133a, miR-133b, miR-134, miR-135a, miR-135b, miR-136, miR-137, miR-138, miR-139, miR-140, miR-141, miR-142-3p, miR-142-5p, miR-143, miR-144, miR-145, miR-146a, miR-146b, miR-147, miR-148a, miR-148b, miR-149, miR-150, miR-151, miR-152, miR-153, miR-154, miR-154*, miR-155, miR-15a, miR-15b, miR-16, miR-17-3p, miR-17-5p, miR-181a, miR-181b, miR-181c, miR-181d, miR-182, miR-182*, miR-183, miR-184, miR-185, miR-186, miR-187, miR-188, miR-189, miR-18a, miR-18a*, miR-18b, miR-190, miR-191, miR-191*, miR-192, miR-193a, miR-193b, miR-194, miR-195, miR-196a, miR-196b, miR-197, miR-198, miR-199a, miR-199a*, miR-199b, miR-19a, miR-19b, miR-200a, miR-200a*, miR-200b, miR-200c, miR-202, miR-202*, miR-203, miR-204, miR-205, miR-206, miR-208, miR-20a, miR-20b, miR-21, miR-210, miR-211, miR-212, miR-213, miR-214, miR-215, miR-216, miR-217, miR-218, miR-219, miR-22, miR-220, miR-221, miR-222, miR-223, miR-224, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-27a, miR-27b, miR-28, miR-296, miR-299-3p, miR-299-5p, miR-29a, miR-29b, miR-29c, miR-301, miR-302a, miR-302a*, miR-302b, miR-302b*, miR-302c, miR-302c*, miR-302d, miR-30a-3p, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-30e-5p, miR-31, miR-32, miR-320, miR-323, miR-324-3p, miR-324-5p, miR-325, miR-326, miR-328, miR-329, miR-33, miR-330, miR-331, miR-335, miR-337, miR-338, miR-339, miR-33b, miR-340, miR-342, miR-345, miR-346, miR-34a, miR-34b, miR-34c, miR-361, miR-362, miR-363, miR-363*, miR-365, miR-367, miR-368, miR-369-3p, miR-369-5p, miR-370, miR-371, miR-372, miR-373, miR-373*, miR-374, miR-375, miR-376a, miR-376a*, miR-376b, miR-377, miR-378, miR-379, miR-380-3p, miR-380-5p, miR-381, miR-382, miR-383, miR-384, miR-409-3p, miR-409-5p, miR-410, miR-411, miR-412, miR-421, miR-422a, miR-422b, miR-423, miR-424, miR-425, miR-425-5p, miR-429, miR-431, miR-432, miR-432*, miR-433, miR-448, miR-449, miR-450, miR-451, miR-452, miR-452*, miR-453, miR-455, miR-483, miR-484, miR-485-3p, miR-485-5p, miR-486, miR-487a, miR-487b, miR-488, miR-489, miR-490, miR-491, miR-492, miR-493, miR-493-3p, miR-494, miR-495, miR-496, miR-497, miR-498, miR-499, miR-500, miR-501, miR-502, miR-503, miR-504, miR-505, miR-506, miR-507, miR-508, miR-509, miR-510, miR-511, miR-512-3p, miR-512-5p, miR-513, miR-514, miR-515-3p, miR-515-5p, miR-516-3p, miR-516-5p, miR-517*, miR-517a, miR-517b, miR-517c, miR-518a, miR-518a-2*, miR-518b, miR-518c, miR-518c*, miR-518d, miR-518e, miR-518f, miR-518f*, miR-519a, miR-519b, miR-519c, miR-519d, miR-519e, miR-519e*, miR-520a, miR-520a*, miR-520b, miR-520c, miR-520d, miR-520d*, miR-520e, miR-520f, miR-520g, miR-520h, miR-521, miR-522, miR-523, miR-524, miR-524*, miR-525, miR-525*, miR-526a, miR-526b, miR-526b*, miR-526c, miR-527, miR-532, miR-542-3p, miR-542-5p, miR-544, miR-545, miR-548a, miR-548b, miR-548c, miR-548th miR-549, miR-550, miR-551a, miR-552, miR-553, miR-554, miR-555, miR-556, miR-557, miR-558, miR-559, miR-560, miR-561, miR-562, miR-563, miR-564, miR-565, miR-566, miR-567, miR-568, miR-569, miR-570, miR-571, miR-572, miR-573, miR-574, miR-575, miR-576, miR-577, miR-578, miR-579, miR-580, miR-581, miR-582, miR-583, miR-584, miR-585, miR-586, miR-587, miR-588, miR-589, miR-590, miR-591, miR-592, miR-593, miR-594, miR-595, miR-596, miR-597, miR-598, miR-599, miR-600, miR-601, miR-602, miR-603, miR-604, miR-605, miR-606, miR-607, miR-608, miR-609, miR-610, miR-611, miR-612, miR-613, miR-614, miR-615, miR-616, miR-617, miR-618, miR-619, miR-620, miR-621, miR-622, miR-623, miR-624, miR-625, miR-626, miR-627, miR-628, miR-629, miR-630, miR-631, miR-632, miR-633, miR-634, miR-635, miR-636, miR-637, miR-638, miR-639, miR-640, miR-641, miR-642, miR-643, miR-644, miR-645, miR-646, miR-647, miR-648, miR-649, miR-650, miR-651, miR-652, miR-653, miR-654, miR-655, miR-656, miR-657, miR-658, miR-659, miR-660, miR-661, miR-662, miR-663, miR-7, miR-9, miR-9*, miR-92, miR-93, miR-95, miR-96, miR-98, miR-99a and miR-99b.

The present invention also provides a biochip for evaluating physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of the subject. The biochip may also contain the probes for all mature microRNAs in human serum/plasma. The probes specifically include the probes as shown in Table 1.

TABLE 1 Probes of all mature microRNAs in human serum/plasma SEQ Corresponding ID NO Probes microRNAs Sequences of probes SEQ probe-let-7a let-7a AACTATACAACCTACTACCTCA ID NO: 001 SEQ probe-let-7b let-7b AACCACACAACCTACTACCTCA ID NO: 002 SEQ probe-let-7c let-7c AACCATACAACCTACTACCTCA ID NO: 003 SEQ probe-let-7d let-7d ACTATGCAACCTACTACCTCT ID NO: 004 SEQ probe-let-7e let-7e ACTATACAACCTCCTACCTCA ID NO: 005 SEQ probe-let-7f let-7f AACTATACAATCTACTACCTCA ID NO: 006 SEQ probe-let-7g let-7g ACTGTACAAACTACTACCTCA ID NO: 007 SEQ probe-let-7i let-7i ACAGCACAAACTACTACCTCA ID NO: 008 SEQ probe-miR-1 miR-1 TACATACTTCTTTACATTCCA ID NO: 009 SEQ probe-miR-100 miR-100 CACAAGTTCGGATCTACGGGTT ID NO: 010 SEQ probe-miR-101 miR-101 CTTCAGTTATCACAGTACTGTA ID NO: 011 SEQ probe-miR-103 miR-103 TCATAGCCCTGTACAATGCTGCT ID NO: 012 SEQ probe-miR-105 miR-105 ACAGGAGTCTGAGCATTTGA ID NO: 013 SEQ probe-miR-106a miR-106a GCTACCTGCACTGTAAGCACTTTT ID NO: 014 SEQ probe-miR-106b miR-106b ATCTGCACTGTCAGCACTTTA ID NO: 015 SEQ probe-miR-107 miR-107 TGATAGCCCTGTACAATGCTGCT ID NO: 016 SEQ probe-miR-10a miR-10a CACAAATTCGGATCTACAGGGTA ID NO: 017 SEQ probe-miR-10b miR-10b ACAAATTCGGTTCTACAGGGTA ID NO: 018 SEQ probe-miR-122a miR-122a ACAAACACCATTGTCACACTCCA ID NO: 019 SEQ probe-miR-124a miR-124a TGGCATTCACCGCGTGCCTTAA ID NO: 020 SEQ probe-miR-125a miR-125a CACAGGTTAAAGGGTCTCAGGGA ID NO: 021 SEQ probe-miR-125b miR-125b TCACAAGTTAGGGTCTCAGGGA ID NO: 022 SEQ probe-miR-126 miR-126 GCATTATTACTCACGGTACGA ID NO: 023 SEQ probe-miR-126* miR-126* CGCGTACCAAAAGTAATAATG ID NO: 024 SEQ probe-miR-127 miR-127 AGCCAAGCTCAGACGGATCCGA ID NO: 025 SEQ probe-miR-128 amiR-128a AAAAGAGACCGGTTCACTGTGA ID NO: 026 SEQ probe-miR-128b miR-128b GAAAGAGACCGGTTCACTGTGA ID NO: 027 SEQ probe-miR-129 miR-129 GCAAGCCCAGACCGCAAAAAG ID NO: 028 SEQ probe-miR-130 amiR-130a ATGCCCTTTTAACATTGCACTG ID NO: 029 SEQ probe-miR-130b miR-130b ATGCCCTTTCATCATTGCACTG ID NO: 030 SEQ probe-miR-132 miR-132 CGACCATGGCTGTAGACTGTTA ID NO: 031 SEQ probe-miR-133a miR-133a ACAGCTGGTTGAAGGGGACCAA ID NO: 032 SEQ probe-miR-133b miR-133b TAGCTGGTTGAAGGGGACCAA ID NO: 033 SEQ probe-miR-134 miR-134 CCCTCTGGTCAACCAGTCACA ID NO: 034 SEQ probe-miR-135a miR-135a TCACATAGGAATAAAAAGCCATA ID NO: 035 SEQ probe-miR-135b miR-135b CACATAGGAATGAAAAGCCATA ID NO: 036 SEQ probe-miR-136 miR-136 TCCATCATCAAAACAAATGGAGT ID NO: 037 SEQ probe-miR-137 miR-137 CTACGCGTATTCTTAAGCAATA ID NO: 038 SEQ probe-miR-138 miR-138 GATTCACAACACCAGCT ID NO: 039 SEQ probe-miR-139 miR-139 AGACACGTGCACTGTAGA ID NO: 040 SEQ probe-miR-140 miR-140 CTACCATAGGGTAAAACCACT ID NO: 041 SEQ probe-miR-141 miR-141 CCATCTTTACCAGACAGTGTTA ID NO: 042 SEQ probe-miR-142-3p miR-142-3p TCCATAAAGTAGGAAACACTACA ID NO: 043 SEQ probe-miR-142-5p miR-142-5p GTAGTGCTTTCTACTTTATG ID NO: 044 SEQ probe-miR-143 miR-143 TGAGCTACAGTGCTTCATCTCA ID NO: 045 SEQ probe-miR-144 miR-144 CTAGTACATCATCTATACTGTA ID NO: 046 SEQ probe-miR-145 miR-145 AAGGGATTCCTGGGAAAACTGGAC ID NO: 047 SEQ probe-miR-146a miR-146a AACCCATGGAATTCAGTTCTCA ID NO: 048 SEQ probe-miR-146b miR-146b AGCCTATGGAATTCAGTTCTCA ID NO: 049 SEQ probe-miR-147 miR-147 GCAGAAGCATTTCCACACAC ID NO: 050 SEQ probe-miR-148a miR-148a ACAAAGTTCTGTAGTGCACTGA ID NO: 051 SEQ probe-miR-148b miR-148b ACAAAGTTCTGTGATGCACTGA ID NO: 052 SEQ probe-miR-149 miR-149 GGAGTGAAGACACGGAGCCAGA ID NO: 053 SEQ probe-miR-150 miR-150 CACTGGTACAAGGGTTGGGAGA ID NO: 054 SEQ probe-miR-151 miR-151 CCTCAAGGAGCTTCAGTCTAGT ID NO: 055 SEQ probe-miR-152 miR-152 CCCAAGTTCTGTCATGCACTGA ID NO: 056 SEQ probe-miR-153 miR-153 TCACTTTTGTGACTATGCAA ID NO: 057 SEQ probe-miR-154 miR-154 CGAAGGCAACACGGATAACCTA ID NO: 058 SEQ probe-miR-154* miR-154* AATAGGTCAACCGTGTATGATT ID NO: 059 SEQ probe-miR-155 miR-155 CCCCTATCACGATTAGCATTAA ID NO: 060 SEQ probe-miR-15a miR-15a CACAAACCATTATGTGCTGCTA ID NO: 061 SEQ probe-miR-15b miR-15b TGTAAACCATGATGTGCTGCTA ID NO: 062 SEQ probe-miR-16 miR-16 CGCCAATATTTACGTGCTGCTA ID NO: 063 SEQ probe-miR-17-3p miR-17-3p ACAAGTGCCTTCACTGCAGT ID NO: 064 SEQ probe-miR-17-5p miR-17-5p ACTACCTGCACTGTAAGCACTTTG ID NO: 065 SEQ probe-miR-181a miR-181a ACTCACCGACAGCGTTGAATGTT ID NO: 066 SEQ probe-miR-181b miR-181b CCCACCGACAGCAATGAATGTT ID NO: 067 SEQ probe-miR-181c miR-181c ACTCACCGACAGGTTGAATGTT ID NO: 068 SEQ probe-miR-181d miR-181d AACCCACCGACAACAATGAATGTT ID NO: 069 SEQ probe-miR-182 miR-182 TGTGAGTTCTACCATTGCCAAA ID NO: 070 SEQ probe-miR-182* miR-182* TAGTTGGCAAGTCTAGAACCA ID NO: 071 SEQ probe-miR-183 miR-183 CAGTGAATTCTACCAGTGCCATA ID NO: 072 SEQ probe-miR-184 miR-184 ACCCTTATCAGTTCTCCGTCCA ID NO: 073 SEQ probe-miR-185 miR-185 GAACTGCCTTTCTCTCCA ID NO: 074 SEQ probe-miR-186 miR-186 AAGCCCAAAAGGAGAATTCTTTG ID NO: 075 SEQ probe-miR-187 miR-187 CGGCTGCAACACAAGACACGA ID NO: 076 SEQ probe-miR-188 miR-188 ACCCTCCACCATGCAAGGGATG ID NO: 077 SEQ probe-miR-189 miR-189 ACTGATATCAGCTCAGTAGGCAC ID NO: 078 SEQ probe-miR-18a miR-18a TATCTGCACTAGATGCACCTTA ID NO: 079 SEQ probe-miR-18a* miR-18a* AGAAGGAGCACTTAGGGCAGT ID NO: 080 SEQ probe-miR-18b miR-18b TAACTGCACTAGATGCACCTTA ID NO: 081 SEQ probe-miR-190 miR-190 ACCTAATATATCAAACATATCA ID NO: 082 SEQ probe-miR-191 miR-191 AGCTGCTTTTGGGATTCCGTTG ID NO: 083 SEQ probe-miR-191* miR-191* GGGGACGAAATCCAAGCGCAGC ID NO: 084 SEQ probe-miR-192 miR-192 GGCTGTCAATTCATAGGTCAG ID NO: 085 SEQ probe-miR-193a miR-193a CTGGGACTTTGTAGGCCAGTT ID NO: 086 SEQ probe-miR-193b miR-193b AAAGCGGGACTTTGAGGGCCAGTT ID NO: 087 SEQ probe-miR-194 miR-194 TCCACATGGAGTTGCTGTTACA ID NO: 088 SEQ probe-miR-195 miR-195 GCCAATATTTCTGTGCTGCTA ID NO: 089 SEQ probe-miR-196a miR-196a CCAACAACATGAAACTACCTA ID NO: 090 SEQ probe-miR-196b miR-196b CCAACAACAGGAAACTACCTA ID NO: 091 SEQ probe-miR-197 miR-197 GCTGGGTGGAGAAGGTGGTGAA ID NO: 092 SEQ probe-miR-198 miR-198 CCTATCTCCCCTCTGGACC ID NO: 093 SEQ probe-miR-199a miR-199a GAACAGGTAGTCTGAACACTGGG ID NO: 094 SEQ probe-miR-199a* miR-199a* AACCAATGTGCAGACTACTGTA ID NO: 095 SEQ probe-miR-199b miR-199b GAACAGATAGTCTAAACACTGGG ID NO: 096 SEQ probe-miR-19a miR-19a TCAGTTTTGCATAGATTTGCACA ID NO: 097 SEQ probe-miR-19b miR-19b TCAGTTTTGCATGGATTTGCACA ID NO: 098 SEQ probe-miR-200a miR-200a ACATCGTTACCAGACAGTGTTA ID NO: 099 SEQ probe-miR-200a* miR-200a* TCCAGCACTGTCCGGTAAGATG ID NO: 100 SEQ probe-miR-200b miR-200b GTCATCATTACCAGGCAGTATTA ID NO: 101 SEQ probe-miR-200c miR-200c CCATCATTACCCGGCAGTATTA ID NO: 102 SEQ probe-miR-202 miR-202 TTTTCCCATGCCCTATACCTCT ID NO: 103 SEQ probe-miR-202* miR-202* AAAGAAGTATATGCATAGGAAA ID NO: 104 SEQ probe-miR-203 miR-203 CTAGTGGTCCTAAACATTTCAC ID NO: 105 SEQ probe-miR-204 miR-204 AGGCATAGGATGACAAAGGGAA ID NO: 106 SEQ probe-miR-205 miR-205 CAGACTCCGGTGGAATGAAGGA ID NO: 107 SEQ probe-miR-206 miR-206 CCACACACTTCCTTACATTCCA ID NO: 108 SEQ probe-miR-208 miR-208 ACAAGCTTTTTGCTCGTCTTAT ID NO: 109 SEQ probe-miR-20a miR-20a CTACCTGCACTATAAGCACTTTA ID NO: 110 SEQ probe-miR-20b miR-20b CTACCTGCACTATGAGCACTTTG ID NO: 111 SEQ probe-miR-21 miR-21 TCAACATCAGTCTGATAAGCTA ID NO: 112 SEQ probe-miR-210 miR-210 TCAGCCGCTGTCACACGCACAG ID NO: 113 SEQ probe-miR-211 miR-211 AGGCGAAGGATGACAAAGGGAA ID NO: 114 SEQ probe-miR-212 miR-212 GGCCGTGACTGGAGACTGTTA ID NO: 115 SEQ probe-miR-213 miR-213 GGTACAATCAACGGTCGATGGT ID NO: 116 SEQ probe-miR-214 miR-214 CTGCCTGTCTGTGCCTGCTGT ID NO: 117 SEQ probe-miR-215 miR-215 GTCTGTCAATTCATAGGTCAT ID NO: 118 SEQ probe-miR-216 miR-216 CACAGTTGCCAGCTGAGATTA ID NO: 119 SEQ probe-miR-217 miR-217 ATCCAATCAGTTCCTGATGCAGTA ID NO: 120 SEQ probe-miR-218 miR-218 ACATGGTTAGATCAAGCACAA ID NO: 121 SEQ probe-miR-219 miR-219 AGAATTGCGTTTGGACAATCA ID NO: 122 SEQ probe-miR-22 miR-22 ACAGTTCTTCAACTGGCAGCTT ID NO: 123 SEQ probe-miR-220 miR-220 AAAGTGTCAGATACGGTGTGG ID NO: 124 SEQ probe-miR-221 miR-221 GAAACCCAGCAGACAATGTAGCT ID NO: 125 SEQ probe-miR-222 miR-222 GAGACCCAGTAGCCAGATGTAGCT ID NO: 126 SEQ probe-miR-223 miR-223 GGGGTATTTGACAAACTGACA ID NO: 127 SEQ probe-miR-224 miR-224 TAAACGGAACCACTAGTGACTTG ID NO: 128 SEQ probe-miR-23a miR-23a GGAAATCCCTGGCAATGTGAT ID NO: 129 SEQ probe-miR-23b miR-23b GGTAATCCCTGGCAATGTGAT ID NO: 130 SEQ probe-miR-24 miR-24 CTGTTCCTGCTGAACTGAGCCA ID NO: 131 SEQ probe-miR-25 miR-25 TCAGACCGAGACAAGTGCAATG ID NO: 132 SEQ probe-miR-26a miR-26a GCCTATCCTGGATTACTTGAA ID NO: 133 SEQ probe-miR-26b miR-26b AACCTATCCTGAATTACTTGAA ID NO: 134 SEQ probe-miR-27a miR-27a GCGGAACTTAGCCACTGTGAA ID NO: 135 SEQ probe-miR-27b miR-27b GCAGAACTTAGCCACTGTGAA ID NO: 136 SEQ probe-miR-28 miR-28 CTCAATAGACTGTGAGCTCCTT ID NO: 137 SEQ probe-miR-296 miR-296 ACAGGATTGAGGGGGGGCCCT ID NO: 138 SEQ probe-miR-299-3p miR-299-3p AAGCGGTTTACCATCCCACATA ID NO: 139 SEQ probe-miR-299-5p miR-299-5p ATGTATGTGGGACGGTAAACCA ID NO: 140 SEQ probe-miR-29a miR-29a AACCGATTTCAGATGGTGCTA ID NO: 141 SEQ probe-miR-29b miR-29b AACACTGATTTCAAATGGTGCTA ID NO: 142 SEQ probe-miR-29c miR-29c ACCGATTTCAAATGGTGCTA ID NO: 143 SEQ probe-miR-301 miR-301 GCTTTGACAATACTATTGCACTG ID NO: 144 SEQ probe-miR-302a miR-302a TCACCAAAACATGGAAGCACTTA ID NO: 145 SEQ probe-miR-302a* miR-302a* AAAGCAAGTACATCCACGTTTA ID NO: 146 SEQ probe-miR-302b miR-302b CTACTAAAACATGGAAGCACTTA ID NO: 147 SEQ probe-miR-302b* miR-302b* AGAAAGCACTTCCATGTTAAAGT ID NO: 148 SEQ probe-miR-302c miR-302c CCACTGAAACATGGAAGCACTTA ID NO: 149 SEQ probe-miR-302c* miR-302c* CAGCAGGTACCCCCATGTTAAA ID NO: 150 SEQ probe-miR-302d miR-302d ACACTCAAACATGGAAGCACTTA ID NO: 151 SEQ probe-miR-30a-3p miR-30a-3p GCTGCAAACATCCGACTGAAAG ID NO: 152 SEQ probe-miR-30a-5p miR-30a-5p CTTCCAGTCGAGGATGTTTACA ID NO: 153 SEQ probe-miR-30b miR-30b AGCTGAGTGTAGGATGTTTACA ID NO: 154 SEQ probe-miR-30c miR-30c GCTGAGAGTGTAGGATGTTTACA ID NO: 155 SEQ probe-miR-30d miR-30d CTTCCAGTCGGGGATGTTTACA ID NO: 156 SEQ probe-miR-30e-3p miR-30e-3p GCTGTAAACATCCGACTGAAAG ID NO: 157 SEQ probe-miR-30e-5p miR-30e-5p TCCAGTCAAGGATGTTTACA ID NO: 158 SEQ probe-miR-31 miR-31 CAGCTATGCCAGCATCTTGCC ID NO: 159 SEQ probe-miR-32 miR-32 GCAACTTAGTAATGTGCAATA ID NO: 160 SEQ probe-miR-320 miR-320 TTCGCCCTCTCAACCCAGCTTTT ID NO: 161 SEQ probe-miR-323 miR-323 AGAGGTCGACCGTGTAATGTGC ID NO: 162 SEQ probe-miR-324-3p miR-324-3p CCAGCAGCACCTGGGGCAGTGG ID NO: 163 SEQ probe-miR-324-5p miR-324-5p ACACCAATGCCCTAGGGGATGCG ID NO: 164 SEQ probe-miR-325 miR-325 ACACTTACTGGACACCTACTAGG ID NO: 165 SEQ probe-miR-326 miR-326 CTGGAGGAAGGGCCCAGAGG ID NO: 166 SEQ probe-miR-328 miR-328 ACGGAAGGGCAGAGAGGGCCAG ID NO: 167 SEQ probe-miR-329 miR-329 AAAGAGGTTAACCAGGTGTGTT ID NO: 168 SEQ probe-miR-33 miR-33 CAATGCAACTACAATGCAC ID NO: 169 SEQ probe-miR-330 miR-330 TCTCTGCAGGCCGTGTGCTTTGC ID NO: 170 SEQ probe-miR-331 miR-331 TTCTAGGATAGGCCCAGGGGC ID NO: 171 SEQ probe-miR-335 miR-335 ACATTTTTCGTTATTGCTCTTGA ID NO: 172 SEQ probe-miR-337 miR-337 AAAGGCATCATATAGGAGCTGGA ID NO: 173 SEQ probe-miR-338 miR-338 TCAACAAAATCACTGATGCTGGA ID NO: 174 SEQ probe-miR-339 miR-339 TGAGCTCCTGGAGGACAGGGA ID NO: 175 SEQ probe-miR-33b miR-33b TGCAATGCAACAGCAATGCAC ID NO: 176 SEQ probe-miR-340 miR-340 GGCTATAAAGTAACTGAGACGGA ID NO: 177 SEQ probe-miR-342 miR-342 GACGGGTGCGATTTCTGTGTGAGA ID NO: 178 SEQ probe-miR-345 miR-345 GCCCTGGACTAGGAGTCAGCA ID NO: 179 SEQ probe-miR-346 miR-346 AGAGGCAGGCATGCGGGCAGACA ID NO: 180 SEQ probe-miR-34a miR-34a AACAACCAGCTAAGACACTGCCA ID NO: 181 SEQ probe-miR-34b miR-34b CAATCAGCTAATGACACTGCCTA ID NO: 182 SEQ probe-miR-34c miR-34c GCAATCAGCTAACTACACTGCCT ID NO: 183 SEQ probe-miR-361 miR-361 GTACCCCTGGAGATTCTGATAA ID NO: 184 SEQ probe-miR-362 miR-362 CTCACACCTAGGTTCCAAGGATT ID NO: 185 SEQ probe-miR-363 miR-363 TTACAGATGGATACCGTGCAAT ID NO: 186 SEQ probe-miR-363* miR-363* AAATTGCATCGTGATCCACCCG ID NO: 187 SEQ probe-miR-365 miR-365 ATAAGGATTTTTAGGGGCATTA ID NO: 188 SEQ probe-miR-367 miR-367 TCACCATTGCTAAAGTGCAATT ID NO: 189 SEQ probe-miR-368 miR-368 AAACGTGGAATTTCCTCTATGT ID NO: 190 SEQ probe-miR-369-3p miR-369-3p AAAGATCAACCATGTATTATT ID NO: 191 SEQ probe-miR-369-5p miR-369-5p GCGAATATAACACGGTCGATCT ID NO: 192 SEQ probe-miR-370 miR-370 CCAGGTTCCACCCCAGCAGGC ID NO: 193 SEQ probe-miR-371 miR-371 ACACTCAAAAGATGGCGGCAC ID NO: 194 SEQ probe-miR-372 miR-372 ACGCTCAAATGTCGCAGCACTTT ID NO: 195 SEQ probe-miR-373 miR-373 ACACCCCAAAATCGAAGCACTTC ID NO: 196 SEQ probe-miR-373* miR-373* GGAAAGCGCCCCCATTTTGAGT ID NO: 197 SEQ probe-miR-374 miR-374 CACTTATCAGGTTGTATTATAA ID NO: 198 SEQ probe-miR-375 miR-375 TCACGCGAGCCGAACGAACAAA ID NO: 199 SEQ probe-miR-376a miR-376a ACGTGGATTTTCCTCTATGAT ID NO: 200 SEQ probe-miR-376a* miR-376a* CTCATAGAAGGAGAATCTACC ID NO: 201 SEQ probe-miR-376b miR-376b AACATGGATTTTCCTCTATGAT ID NO: 202 SEQ probe-miR-377 miR-377 ACAAAAGTTGCCTTTGTGTGAT ID NO: 203 SEQ probe-miR-378 miR-378 ACACAGGACCTGGAGTCAGGAG ID NO: 204 SEQ probe-miR-379 miR-379 TACGTTCCATAGTCTACCA ID NO: 205 SEQ probe-miR-380-3p miR-380-3p AAGATGTGGACCATATTACATA ID NO: 206 SEQ probe-miR-380-5p miR-380-5p GCGCATGTTCTATGGTCAACCA ID NO: 207 SEQ probe-miR-381 miR-381 ACAGAGAGCTTGCCCTTGTATA ID NO: 208 SEQ probe-miR-382 miR-382 CGAATCCACCACGAACAACTTC ID NO: 209 SEQ probe-miR-383 miR-383 AGCCACAATCACCTTCTGATCT ID NO: 210 SEQ probe-miR-384 miR-384 TATGAACAATTTCTAGGAAT ID NO: 211 SEQ probe-miR-409-3p miR-409-3p AGGGGTTCACCGAGCAACATTCG ID NO: 212 SEQ probe-miR-409-5p miR-409-5p TGCAAAGTTGCTCGGGTAACCT ID NO: 213 SEQ probe-miR-410 miR-410 AACAGGCCATCTGTGTTATATT ID NO: 214 SEQ probe-miR-411 miR-411 CGTACGCTATACGGTCTACTA ID NO: 215 SEQ probe-miR-412 miR-412 ACGGCTAGTGGACCAGGTGAAGT ID NO: 216 SEQ probe-miR-421 miR-421 GCGCCCAATTAATGTCTGTTGAT ID NO: 217 SEQ probe-miR-422a miR-422a GGCCTTCTGACCCTAAGTCCAG ID NO: 218 SEQ probe-miR-422b miR-422b GGCCTTCTGACTCCAAGTCCAG ID NO: 219 SEQ probe-miR-423 miR-423 CTGAGGGGCCTCAGACCGAGCT ID NO: 220 SEQ probe-miR-424 miR-424 TTCAAAACATGAATTGCTGCTG ID NO: 221 SEQ probe-miR-425 miR-425 GGCGGACACGACATTCCCGAT ID NO: 222 SEQ probe-miR-425-5p miR-425-5p TCAACGGGAGTGATCGTGTCATT ID NO: 223 SEQ probe-miR-429 miR-429 ACGGTTTTACCAGACAGTATTA ID NO: 224 SEQ probe-miR-431 miR-431 TGCATGACGGCCTGCAAGACA ID NO: 225 SEQ probe-miR-432 miR-432 CCACCCAATGACCTACTCCAAGA ID NO: 226 SEQ probe-miR-432* miR-432* AGACATGGAGGAGCCATCCAG ID NO: 227 SEQ probe-miR-433 miR-433 ACACCGAGGAGCCCATCATGAT ID NO: 228 SEQ probe-miR-448 miR-448 ATGGGACATCCTACATATGCAA ID NO: 229 SEQ probe-miR-449 miR-449 ACCAGCTAACAATACACTGCCA ID NO: 230 SEQ probe-miR-450 miR-450 TATTAGGAACACATCGCAAAAA ID NO: 231 SEQ probe-miR-451 miR-451 AAACTCAGTAATGGTAACGGTTT ID NO: 232 SEQ probe-miR-452 miR-452 GTCTCAGTTTCCTCTGCAAACA ID NO: 233 SEQ probe-miR-452* miR-452* CTTCTTTGCAGATGAGACTGA ID NO: 234 SEQ probe-miR-453 miR-453 CGAACTCACCACGGACAACCTC ID NO: 235 SEQ probe-miR-455 miR-455 CGATGTAGTCCAAAGGCACATA ID NO: 236 SEQ probe-miR-483 miR-483 AGAAGACGGGAGGAGAGGAGTGA ID NO: 237 SEQ probe-miR-484 miR-484 ATCGGGAGGGGACTGAGCCTGA ID NO: 238 SEQ probe-miR-485-3p miR-485-3p AGAGGAGAGCCGTGTATGAC ID NO: 239 SEQ probe-miR-485-5p miR-485-5p GAATTCATCACGGCCAGCCTCT ID NO: 240 SEQ probe-miR-486 miR-486 CTCGGGGCAGCTCAGTACAGGA ID NO: 241 SEQ probe-miR-487a miR-487a AACTGGATGTCCCTGTATGATT ID NO: 242 SEQ probe-miR-487b miR-487b AAGTGGATGACCCTGTACGATT ID NO: 243 SEQ probe-miR-488 miR-488 TTGAGAGTGCCATTATCTGGG ID NO: 244 SEQ probe-miR-489 miR-489 GCTGCCGTATATGTGATGTCACT ID NO: 245 SEQ probe-miR-490 miR-490 CAGCATGGAGTCCTCCAGGTTG ID NO: 246 SEQ probe-miR-491 miR-491 TCCTCATGGAAGGGTTCCCCACT ID NO: 247 SEQ probe-miR-492 miR-492 AAGAATCTTGTCCCGCAGGTCCT ID NO: 248 SEQ probe-miR-493 miR-493 AATGAAAGCCTACCATGTACAA ID NO: 249 SEQ probe-miR-493-3p miR-493-3p CTGGCACACAGTAGACCTTCA ID NO: 250 SEQ probe-miR-494 miR-494 AAGAGGTTTCCCGTGTATGTTTCA ID NO: 251 SEQ probe-miR-495 miR-495 AAAGAAGTGCACCATGTTTGTTT ID NO: 252 SEQ probe-miR-496 miR-496 GAGATTGGCCATGTAAT ID NO: 253 SEQ probe-miR-497 miR-497 ACAAACCACAGTGTGCTGCTG ID NO: 254 SEQ probe-miR-498 miR-498 GAAAAACGCCCCCTGGCTTGAAA ID NO: 255 SEQ probe-miR-499 miR-499 TTAAACATCACTGCAAGTCTTAA ID NO: 256 SEQ probe-miR-500 miR-500 CAGAATCCTTGCCCAGGTGCAT ID NO: 257 SEQ probe-miR-501 miR-501 TCTCACCCAGGGACAAAGGATT ID NO: 258 SEQ probe-miR-502 miR-502 TAGCACCCAGATAGCAAGGAT ID NO: 259 SEQ probe-miR-503 miR-503 CTGCAGAACTGTTCCCGCTGCTA ID NO: 260 SEQ probe-miR-504 miR-504 ATAGAGTGCAGACCAGGGTCT ID NO: 261 SEQ probe-miR-505 miR-505 GAGGAAACCAGCAAGTGTTGAC ID NO: 262 SEQ probe-miR-506 miR-506 TCTACTCAGAAGGGTGCCTTA ID NO: 263 SEQ probe-miR-507 miR-507 TTCACTCCAAAAGGTGCAAAA ID NO: 264 SEQ probe-miR-508 miR-508 TCTACTCCAAAAGGCTACAATCA ID NO: 265 SEQ probe-miR-509 miR-509 TCTACCCACAGACGTACCAATCA ID NO: 266 SEQ probe-miR-510 miR-510 TGTGATTGCCACTCTCCTGAGTA ID NO: 267 SEQ probe-miR-511 miR-511 TGACTGCAGAGCAAAAGACAC ID NO: 268 SEQ probe-miR-512-3p miR-512-3p GACCTCAGCTATGACAGCACTT ID NO: 269 SEQ probe-miR-512-5p miR-512-5p GAAAGTGCCCTCAAGGCTGAGTG ID NO: 270 SEQ probe-miR-513 miR-513 ATAAATGACACCTCCCTGTGAA ID NO: 271 SEQ probe-miR-514 miR-514 CTACTCACAGAAGTGTCAAT ID NO: 272 SEQ probe-miR-515-3p miR-515-3p ACGCTCCAAAAGAAGGCACTC ID NO: 273 SEQ probe-miR-515-5p miR-515-5p CAGAAAGTGCTTTCTTTTGGAGAA ID NO: 274 SEQ probe-miR-516-3p miR-516-3p ACCCTCTGAAAGGAAGCA ID NO: 275 SEQ probe-miR-516-5p miR-516-5p AAAGTGCTTCTTACCTCCAGAT ID NO: 276 SEQ probe-miR-517* miR-517* AGACAGTGCTTCCATCTAGAGG ID NO: 277 SEQ probe-miR-517a miR-517a AACACTCTAAAGGGATGCACGAT ID NO: 278 SEQ probe-miR-517b miR-517b AACACTCTAAAGGGATGCACGA ID NO: 279 SEQ probe-miR-517c miR-517c ACACTCTAAAAGGATGCACGAT ID NO: 280 SEQ probe-miR-518a miR-518a TCCAGCAAAGGGAAGCGCTTT ID NO: 281 SEQ probe-miR-518a-2* miR-518a-2* AAAGGGCTTCCCTTTGCAGA ID NO: 282 SEQ probe-miR-518b miR-518b ACCTCTAAAGGGGAGCGCTTTG ID NO: 283 SEQ probe-miR-518c miR-518c CACTCTAAAGAGAAGCGCTTTG ID NO: 284 SEQ probe-miR-518c* miR-518c* CAGAAAGTGCTTCCCTCCAGAGA ID NO: 285 SEQ probe-miR-518d miR-518d GCTCCAAAGGGAAGCGCTTTG ID NO: 286 SEQ probe-miR-518e miR-518e ACACTCTGAAGGGAAGCGCTTT ID NO: 287 SEQ probe-miR-518f miR-518f TCCTCTAAAGAGAAGCGCTTT ID NO: 288 SEQ probe-miR-518f* miR-518f* AGAGAAAGTGCTTCCCTCTAGAG ID NO: 289 SEQ probe-miR-519a miR-519a GTAACACTCTAAAAGGATGCACTTT ID NO: 290 SEQ probe-miR-519b miR-519b AAACCTCTAAAAGGATGCACTTT ID NO: 291 SEQ probe-miR-519c miR-519c ATCCTCTAAAAAGATGCACTTT ID NO: 292 SEQ probe-miR-519d miR-519d ACACTCTAAAGGGAGGCACTTTG ID NO: 293 SEQ probe-miR-519e miR-519e ACACTCTAAAAGGAGGCACTTT ID NO: 294 SEQ probe-miR-519e* miR-519e* GAAAGTGCTCCCTTTTGGAGAA ID NO: 295 SEQ probe-miR-520a miR-520a ACAGTCCAAAGGGAAGCACTTT ID NO: 296 SEQ probe-miR-520a* miR-520a* AGAAAGTACTTCCCTCTGGAG ID NO: 297 SEQ probe-miR-520b miR-520b CCCTCTAAAAGGAAGCACTTT ID NO: 298 SEQ probe-miR-520c miR-520c AACCCTCTAAAAGGAAGCACTTT ID NO: 299 SEQ probe-miR-520d miR-520d AACCCACCAAAGAGAAGCACTTT ID NO: 300 SEQ probe-miR-520d* miR-520d* CAGAAAGGGCTTCCCTTTGTAGA ID NO: 301 SEQ probe-miR-520e miR-520e CCCTCAAAAAGGAAGCACTTT ID NO: 302 SEQ probe-miR-520f miR-520f AACCCTCTAAAAGGAAGCACTT ID NO: 303 SEQ probe-miR-520g miR-520g ACACTCTAAAGGGAAGCACTTTGT ID NO: 304 SEQ probe-miR-520h miR-520h ACTCTAAAGGGAAGCACTTTGT ID NO: 305 SEQ probe-miR-521 miR-521 ACACTCTAAAGGGAAGTGCGTT ID NO: 306 SEQ probe-miR-522 miR-522 AACACTCTAAAGGGAACCATTTT ID NO: 307 SEQ probe-miR-523 miR-523 CCCTCTATAGGGAAGCGCGTT ID NO: 308 SEQ probe-miR-524 miR-524 ACTCCAAAGGGAAGCGCCTTC ID NO: 309 SEQ probe-miR-524* miR-524* GAGAAAGTGCTTCCCTTTGTAG ID NO: 310 SEQ probe-miR-525 miR-525 AGAAAGTGCATCCCTCTGGAG ID NO: 311 SEQ probe-miR-525* miR-525* GCTCTAAAGGGAAGCGCCTTC ID NO: 312 SEQ probe-miR-526a miR-526a AGAAAGTGCTTCCCTCTAGAG ID NO: 313 SEQ probe-miR-526b miR-526b AACAGAAAGTGCTTCCCTCAAGAG ID NO: 314 SEQ probe-miR-526b* miR-526b* GCCTCTAAAAGGAAGCACTTT ID NO: 315 SEQ probe-miR-526c miR-526c AACAGAAAGCGCTTCCCTCTAGAG ID NO: 316 SEQ probe-miR-527 miR-527 AGAAAGGGCTTCCCTTTGCAG ID NO: 317 SEQ probe-miR-532 miR-532 ACGGTCCTACACTCAAGGCATG ID NO: 318 SEQ probe-miR-542-3p miR-542-3p TTTCAGTTATCAATCTGTCACA ID NO: 319 SEQ probe-miR-542-5p miR-542-5p CTCGTGACATGATGATCCCCGA ID NO: 320 SEQ probe-miR-544 miR-544 ACTTGCTAAAAATGCAGAAT ID NO: 321 SEQ probe-miR-545 miR-545 CACACAATAAATGTTTGCTGAT ID NO: 322 SEQ probe-miR-548a miR-548a GCAAAAGTAATTGCCAGTTTTG ID NO: 323 SEQ probe-miR-548b miR-548b ACAAAAGCAACTGAGGTTCTTG ID NO: 324 SEQ probe-miR-548c miR-548c GCAAAAGTAATTGAGATTTTTG ID NO: 325 SEQ probe-miR-548d miR-548d GCAAAAGAAACTGTGGTTTTTG ID NO: 326 SEQ probe-miR-549 miR-549 AGAGCTCATCCATAGTTGTCA ID NO: 327 SEQ probe-miR-550 miR-550 ATGTGCCTGAGGGAGTAAGACA ID NO: 328 SEQ probe-miR-551a miR-551a TGGAAACCAAGAGTGGGTCGC ID NO: 329 SEQ probe-miR-552 miR-552 TTGTCTAACCAGTCACCTGTT ID NO: 330 SEQ probe-miR-553 miR-553 AAAACAAAATCTCACCGTTTT ID NO: 331 SEQ probe-miR-554 miR-554 ACTGGCTGAGTCAGGACTAGC ID NO: 332 SEQ probe-miR-555 miR-555 ATCAGAGGTTCAGCTTACCCT ID NO: 333 SEQ probe-miR-556 miR-556 CATATTACAATGAGCTCATC ID NO: 334 SEQ probe-miR-557 miR-557 AGACAAGGCCCACCCGTGCAAAC ID NO: 335 SEQ probe-miR-558 miR-558 ATTTTGGTACAGCAGCTCA ID NO: 336 SEQ probe-miR-559 miR-559 TTTTGGTGCATATTTACTTTA ID NO: 337 SEQ probe-miR-560 miR-560 GGCGGCCGGCCGGCGCACGC ID NO: 338 SEQ probe-miR-561 miR-561 ACTTCAAGGATCTTAAACTTTG ID NO: 339 SEQ probe-miR-562 miR-562 GCAAATGGTACAGCTACTTT ID NO: 340 SEQ probe-miR-563 miR-563 GGGAAACGTATGTCAACCT ID NO: 341 SEQ probe-miR-564 miR-564 GCCTGCTGACACCGTGCCT ID NO: 342 SEQ probe-miR-565 miR-565 AAACAGACATCGCGAGCCAGCC ID NO: 343 SEQ probe-miR-566 miR-566 GTTGGGATCACAGGCGCCC ID NO: 344 SEQ probe-miR-567 miR-567 GTTCTGTCCTGGAAGAACATACT ID NO: 345 SEQ probe-miR-568 miR-568 GTGTGTATACATTTATACAT ID NO: 346 SEQ probe-miR-569 miR-569 ACTTTCCAGGATTCATTAACT ID NO: 347 SEQ probe-miR-570 miR-570 TGCAAAGGTAATTGCTGTTTTC ID NO: 348 SEQ probe-miR-571 miR-571 CTCACTCAGATGGCCAACTCA ID NO: 349 SEQ probe-miR-572 miR-572 TGGGCCACCGCCGAGCGGAC ID NO: 350 SEQ probe-miR-573 miR-573 CTGATCAGTTACACATCACTTCAG ID NO: 351 SEQ probe-miR-574 miR-574 GTGGGTGTGTGCATGAGCGTG ID NO: 352 SEQ probe-miR-575 miR-575 GCTCCTGTCCAACTGGCTC ID NO: 353 SEQ probe-miR-576 miR-576 CAAAGACGTGGAGAAATTAGAAT ID NO: 354 SEQ probe-miR-577 miR-577 CAGGTACCAATATTTTATCTA ID NO: 355 SEQ probe-miR-578 miR-578 ACAATCCTAGAGCACAAGAAG ID NO: 356 SEQ probe-miR-579 miR-579 ATCGCGGTTTATACCAAATGAAT ID NO: 357 SEQ probe-miR-580 miR-580 CCTAATGATTCATCATTCTCAA ID NO: 358 SEQ probe-miR-581 miR-581 ACTGATCTAGAGAACACAAGA ID NO: 359 SEQ probe-miR-582 miR-582 AGTAACTGGTTGAACAACTGTAA ID NO: 360 SEQ probe-miR-583 miR-583 GTAATGGGACCTTCCTCTTTG ID NO: 361 SEQ probe-miR-584 miR-584 CTCAGTCCCAGGCAAACCATAA ID NO: 362 SEQ probe-miR-585 miR-585 TAGCATACAGATACGCCCA ID NO: 363 SEQ probe-miR-586 miR-586 GGACCTAAAAATACAATGCATA ID NO: 364 SEQ probe-miR-587 miR-587 GTGACTCATCACCTATGGAAA ID NO: 365 SEQ probe-miR-588 miR-588 GTTCTAACCCATTGTGGCCAA ID NO: 366 SEQ probe-miR-589 miR-589 TCTGGGAACCGGCATTTGTTCTGA ID NO: 367 SEQ probe-miR-590 miR-590 CTGCACTTTTATGAATAAGCTC ID NO: 368 SEQ probe-miR-591 miR-591 ACAATGAGAACCCATGGTCT ID NO: 369 SEQ probe-miR-592 miR-592 ACATCATCGCATATTGACACAA ID NO: 370 SEQ probe-miR-593 miR-593 GCTGAGCAATGCCTGGCTGGTGCCT ID NO: 371 SEQ probe-miR-594 miR-594 AAAGTCACAGGCCACCCCAGATGGG ID NO: 372 SEQ probe-miR-595 miR-595 AGACACACCACGGCACACTTC ID NO: 373 SEQ probe-miR-596 miR-596 CCCGAGGAGCCGGGCAGGCTT ID NO: 374 SEQ probe-miR-597 miR-597 ACAGTGGTCATCGAGTGACACA ID NO: 375 SEQ probe-miR-598 miR-598 TGACGATGACAACGATGACGTA ID NO: 376 SEQ probe-miR-599 miR-599 GTTTGATAAACTGACACAAC ID NO: 377 SEQ probe-miR-600 miR-600 GAGCAAGGCTCTTGTCTGTAAGT ID NO: 378 SEQ probe-miR-601 miR-601 CTCCTCCAACAATCCTAGACCA ID NO: 379 SEQ probe-miR-602 miR-602 GGGCCGCAGCTGTCGCCCGTGTC ID NO: 380 SEQ probe-miR-603 miR-603 GCAAAAGTAATTGCAGTGTGTG ID NO: 381 SEQ probe-miR-604 miR-604 GTCCTGAATTCCGCAGCCT ID NO: 382 SEQ probe-miR-605 miR-605 AGGAGAAGGCACCATGGGATTTA ID NO: 383 SEQ probe-miR-606 miR-606 ATCTTTGATTTTCAGTAGTTT ID NO: 384 SEQ probe-miR-607 miR-607 GTTATAGATCTGGATTTGAAC ID NO: 385 SEQ probe-miR-608 miR-608 ACGGAGCTGTCCCAACACCACCCCT ID NO: 386 SEQ probe-miR-609 miR-609 AGAGATGAGAGAAACACCCT ID NO: 387 SEQ probe-miR-610 miR-610 TCCCAGCACACATTTAGCTCA ID NO: 388 SEQ probe-miR-611 miR-611 GTCAGACCCCGAGGGGTCCTCGC ID NO: 389 SEQ probe-miR-612 miR-612 AAGGAGCTCAGAAGCCCTGCCCAGC ID NO: 390 SEQ probe-miR-613 miR-613 GGCAAAGAAGGAACATTCCT ID NO: 391 SEQ probe-miR-614 miR-614 CCACCTGGCAAGAACAGGCGTTC ID NO: 392 SEQ probe-miR-615 miR-615 AGAGGGAGACCCAGGCTCGGA ID NO: 393 SEQ probe-miR-616 miR-616 AAGTCACTGAAGGGTTTTGAGT ID NO: 394 SEQ probe-miR-617 miR-617 GCCACCTTCAAATGGGAAGTCT ID NO: 395 SEQ probe-miR-618 miR-618 ACTCAGAAGGACAAGTAGAGTTT ID NO: 396 SEQ probe-miR-619 miR-619 ACTGGGCACAAACATGTCCAGGTC ID NO: 397 SEQ probe-miR-620 miR-620 ATTTCTATATCTATCTCCAT ID NO: 398 SEQ probe-miR-621 miR-621 AGGTAAGCGCTGTTGCTAGCC ID NO: 399 SEQ probe-miR-622 miR-622 GCTCCAACCTCAGCAGACTGT ID NO: 400 SEQ probe-miR-623 miR-623 ACCCAACAGCCCCTGCAAGGGAT ID NO: 401 SEQ probe-miR-624 miR-624 TGAACACAAGGTACTGGTACTA ID NO: 402 SEQ probe-miR-625 miR-625 AGGACTATAGAACTTTCCCCCT ID NO: 403 SEQ probe-miR-626 miR-626 AAGACATTTTCAGACAGCT ID NO: 404 SEQ probe-miR-627 miR-627 TCCTCTTTTCTTAGAGACTCAC ID NO: 405 SEQ probe-miR-628 miR-628 CGACTGCCACTCTTACTAGA ID NO: 406 SEQ probe-miR-629 miR-629 GCTGGGCTTACGTTGGGAGAAC ID NO: 407 SEQ probe-miR-630 miR-630 ACCTTCCCTGGTACAGAATACT ID NO: 408 SEQ probe-miR-631 miR-631 GCTGAGGTCTGGGCCAGGTCT ID NO: 409 SEQ probe-miR-632 miR-632 TCCCACAGGAAGCAGACAC ID NO: 410 SEQ probe-miR-633 miR-633 TTTATTGTGGTAGATACTATTAG ID NO: 411 SEQ probe-miR-634 miR-634 GTCCAAAGTTGGGGTGCTGGTT ID NO: 412 SEQ probe-miR-635 miR-635 GGACATTGTTTCAGTGCCCAAGT ID NO: 413 SEQ probe-miR-636 miR-636 CTGCGGGCGGGACGAGCAAGCACA ID NO: 414 SEQ probe-miR-637 miR-637 ACGCAGAGCCCGAAAGCCCCCAGT ID NO: 415 SEQ probe-miR-638 miR-638 AGGCCGCCACCCGCCCGCGATCCCT ID NO: 416 SEQ probe-miR-639 miR-639 ACAGCGCTCGCAACCGCAGCGAT ID NO: 417 SEQ probe-miR-640 miR-640 AGAGGCAGGTTCCTGGATCAT ID NO: 418 SEQ probe-miR-641 miR-641 GAGGTGACTCTATCCTATGTCTTT ID NO: 419 SEQ probe-miR-642 miR-642 CAAGACACATTTGGAGAGGGAC ID NO: 420 SEQ probe-miR-643 miR-643 CTACCTGAGCTAGCATACAAGT ID NO: 421 SEQ probe-miR-644 miR-644 GCTCTAAGAAAGCCACACT ID NO: 422 SEQ probe-miR-645 miR-645 TCAGCAGTACCAGCCTAGA ID NO: 423 SEQ probe-miR-646 miR-646 GCCTCAGAGGCAGCTGCTT ID NO: 424 SEQ probe-miR-647 miR-647 GAAGGAAGTGAGTGCAGCCAC ID NO: 425 SEQ probe-miR-648 miR-648 ACCAGTGCCCTGCACACTT ID NO: 426 SEQ probe-miR-649 miR-649 GACTCTTGAACAACACAGGTTT ID NO: 427 SEQ probe-miR-650 miR-650 GTCCTGAGAGCGCTGCCTCCT ID NO: 428 SEQ probe-miR-651 miR-651 CAAAAGTCAAGCTTATCCTAAA ID NO: 429 SEQ probe-miR-652 miR-652 TGCACAACCCTAGTGGCGCCATT ID NO: 430 SEQ probe-miR-653 miR-653 GTTCAGTAGAGATTGTTTCAA ID NO: 431 SEQ probe-miR-654 miR-654 GCACATGTTCTGCGGCCCACCA ID NO: 432 SEQ probe-miR-655 miR-655 AAAGAGGTTAACCATGTATTAT ID NO: 433 SEQ probe-miR-656 miR-656 AGAGGTTGACTGTATAATATT ID NO: 434 SEQ probe-miR-657 miR-657 CCTAGAGAGGGTGAGAACCTGCC ID NO: 435 SEQ probe-miR-658 miR-658 ACCAACGGACCTACTTCCCTCCGCC ID NO: 436 SEQ probe-miR-659 miR-659 TGGGGACCCTCCCTGAACCAAG ID NO: 437 SEQ probe-miR-660 miR-660 CAACTCCGATATGCAATGGGTA ID NO: 438 SEQ probe-miR-661 miR-661 ACGCGCAGGCCAGAGACCCAGGCA ID NO: 439 SEQ probe-miR-662 miR-662 CTGCTGGGCCACAACGTGGGA ID NO: 440 SEQ probe-miR-663 miR-663 GCGGTCCCGCGGCGCCCCGCCT ID NO: 441 SEQ probe-miR-7 miR-7 CAACAAAATCACTAGTCTTCCA ID NO: 442 SEQ probe-miR-9 miR-9 TCATACAGCTAGATAACCAAAGA ID NO: 443 SEQ probe-miR-9* miR-9* ACTTTCGGTTATCTAGCTTTA ID NO: 444 SEQ probe-miR-92 miR-92 CAGGCCGGGACAAGTGCAATA ID NO: 445 SEQ probe-miR-93 miR-93 CTACCTGCACGAACAGCACTTT ID NO: 446 SEQ probe-miR-95 miR-95 TGCTCAATAAATACCCGTTGAA ID NO: 447 SEQ probe-miR-96 miR-96 GCAAAAATGTGCTAGTGCCAAA ID NO: 448 SEQ probe-miR-98 miR-98 AACAATACAACTTACTACCTCA ID NO: 449 SEQ probe-miR-99a miR-99a CACAAGATCGGATCTACGGGTT ID NO: 450 SEQ probe-miR-99b miR-99b CGCAAGGTCGGTTCTACGGGTG ID NO: 451

Specifically, among the above-mentioned combinations, methods, kits or biochips, the said evaluation of the physiological and/or pathological condition of a subject is to determine the physiological and/or pathological condition of the subject after being administrated a test sample, which is specifically useful for screening the test sample for the activities on the prevention and/or treatment of diseases; the said evaluation of the physiological and/or pathological condition of a subject is to diagnose and/or differentially diagnose the diseases of the subject; the said evaluation of the physiological and/or pathological condition of a subject is to evaluate the effectiveness of the treatment on the diseases of the subject; the said evaluation of the physiological and/or pathological condition of a subject is to predict the disease occurrence of the subject, which is specifically the occurrence of complications and/or the relapse of malignant diseases; the above-mentioned combinations, methods, kits or biochips can also be useful for detecting the subject for prohibited drugs-taking.

The above-mentioned diseases include a variety of tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary, diseases of reproductive system and diseases of locomotor system.

The above-mentioned serum/plasma derives from the living bodies, tissues, organs and/or corpuses of the subject.

The problems to be solved by the present invention include: (1) analyzing and identifying the microRNA molecules and their stability in serum/plasma of a variety of animals such as human, mice and rats; (2) studying the specificity changes of microRNAs in serum/plasma during the course of various clinical diseases including a variety of tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system; (3) detecting the respective changes of microRNAs in serum/plasma for different diseases through biochip and sequencing technology for microRNAs in serum/plasma; (4) screening a kind of microRNA molecules in serum/plasma which have relatively greater differential expression during the course of diseases and normal physiological conditions to develop detection technologies for serum/plasma microRNAs, and then preparing biochips and diagnostic kits useful for disease diagnosis etc.

Specifically, the present invention analyzes and identifies the existence of microRNA molecules in serum/plasma of various animals such as human, mice and rats through the methods of RT-PCR, Real-time PCR, Northern blotting, RNase protection assay, Solexa sequencing technology and biochip. The stability of microRNAs in serum/plasma is studied by comparing the changes of microRNAs by the effect of DNase and RNase. The existence of serum/plasma microRNAs molecules and the correctness of their sequences are further verified through sequencing and comparing the PCR products of serum/plasma microRNAs.

The detailed preparation and analysis for serum/plasma microRNAs are as follows:

RT-PCR method: collecting serum/plasma samples; conducting reverse transcription reaction on serum/plasma samples to prepare cDNA samples, or extracting total RNA of serum/plasma with Trizol reagent and then conducting reverse transcription reaction so as to prepare cDNA samples; designing a primer through mature microRNAs so as to conduct PCR reaction; carrying out agarose gel electrophoresis with the products of PCR; and observing and taking photographs for the results under ultraviolet lamp after EB staining.

Real-time PCR method: collecting serum/plasma samples; conducting reverse transcription reaction on serum/plasma samples to prepare cDNA samples, or extracting total RNA of serum/plasma with Trizol reagent and then conducting reverse transcription reaction so as to prepare cDNA samples; designing a primer of PCR through mature microRNAs and adding a fluorescent probe EVA GREEN so as to carry out PCR reaction; analyzing and processing the data and then comparing the results.

Northern blotting method: collecting serum/plasma samples; extracting total RNA of serum/plasma with Trizol reagent; conducting denaturing PAGE-electrophoresis and membrane transferring experiment; preparing isotope-labeled microRNA probes; conducting membrane hybridization reaction; detecting the isotope signal for results such as using phosphor-screen scanning technology.

RNase protection assay: firstly synthesizing an antisense RNA probe, labelling it with isotopes and purifying it; collecting serum/plasma samples and extracting RNA; dissolving the extracted DNA in a hybrid buffer and then adding an antisense RNA probe so as to conduct hybridization reaction; adding a RNase digestion solution to irritate reaction; subjecting the resultant material to electrophoresis and radioautography; and analyzing the results.

Solexa sequencing technology: collecting serum/plasma samples; extracting total RNA of serum/plasma with Trizol reagent; conducting PAGE-electrophoresis to recover RNA molecules of 17˜27 nt; enzyme-linking adaptor prime to the 3′ and 5′ end of small RNA molecules respectively; conducting RT-PCR reaction prior to sequencing; and analyzing and processing the data.

Biochip method: arraying a library of all over 500 mature microRNAs to prepare biochips; collecting serum/plasma samples; extracting total RNA of serum/plasma; separating microRNAs by column separation; fluorescently-labelling microRNAs by use of T4 RNA ligase; conducting hybridization reaction with a biochip; and detecting and analyzing the data.

The change trend and change volume of serum/plasma microRNAs during various diseases and their relevancy with various diseases are analyzed through the above-mentioned technologies of RT-PCR, Real-time PCR, Northern blotting, RNase protection assay, Solexa sequencing technology, Biochip, etc. Among others, what to do firstly is to detect and analyze the changes of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, miR-1, miR-100, miR-101, miR-103, miR-105, miR-106a, miR-106b, miR-107, miR-10a, miR-10b, miR-122a, miR-124a, miR-125a, miR-125b, miR-126, miR-126*, miR-127, miR-128a, miR-128b, miR-129, miR-130a, miR-130b, miR-132, miR-133a, miR-133b, miR-134, miR-135a, miR-135b, miR-136, miR-137, miR-138, miR-139, miR-140, miR-141, miR-142-3p, miR-142-5p, miR-143, miR-144, miR-145, miR-146a, miR-146b, miR-147, miR-148a, miR-148b, miR-149, miR-150, miR-151, miR-152, miR-153, miR-154, miR-154*, miR-155, miR-15a, miR-15b, miR-16, miR-17-3p, miR-17-5p, miR-181a, miR-181b, miR-181c, miR-181d, miR-182, miR-182*, miR-183, miR-184, miR-185, miR-186, miR-187, miR-188, miR-189, miR-18a, miR-18a*, miR-18b, miR-190, miR-191, miR-191*, miR-192, miR-193a, miR-193b, miR-194, miR-195, miR-196a, miR-196b, miR-197, miR-198, miR-199a, miR-199a*, miR-199b, miR-19a, miR-19b, miR-200a, miR-200a*, miR-200b, miR-200c, miR-202, miR-202*, miR-203, miR-204, miR-205, miR-206, miR-208, miR-20a, miR-20b, miR-21, miR-210, miR-211, miR-212, miR-213, miR-214, miR-215, miR-216, miR-217, miR-218, miR-219, miR-22, miR-220, miR-221, miR-222, miR-223, miR-224, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-26b, miR-27a, miR-27b, miR-28, miR-296, miR-299-3p, miR-299-5p, miR-29a, miR-29b, miR-29c, miR-301, miR-302a, miR-302a*, miR-302b, miR-302b*, miR-302c, miR-302c*, miR-302d, miR-30a-3p, miR-30a-5p, miR-30b, miR-30c, miR-30d, miR-30e-3p, miR-30e-5p, miR-31, miR-32, miR-320, miR-323, miR-324-3p, miR-324-5p, miR-325, miR-326, miR-328, miR-329, miR-33, miR-330, miR-331, miR-335, miR-337, miR-338, miR-339, miR-33b, miR-340, miR-342, miR-345, miR-346, miR-34a, miR-34b, miR-34c, miR-361, miR-362, miR-363, miR-363*, miR-365, miR-367, miR-368, miR-369-3p, miR-369-5p, miR-370, miR-371, miR-372, miR-373, miR-373*, miR-374, miR-375, miR-376a, miR-376a*, miR-376b, miR-377, miR-378, miR-379, miR-380-3p, miR-380-5p, miR-381, miR-382, miR-383, miR-384, miR-409-3p, miR-409-5p, miR-410, miR-411, miR-412, miR-421, miR-422a, miR-422b, miR-423, miR-424, miR-425, miR-425-5p, miR-429, miR-431, miR-432, miR-432*, miR-433, miR-448, miR-449, miR-450, miR-451, miR-452, miR-452*, miR-453, miR-455, miR-483, miR-484, miR-485-3p, miR-485-5p, miR-486, miR-487a, miR-487b, miR-488, miR-489, miR-490, miR-491, miR-492, miR-493, miR-493-3p, miR-494, miR-495, miR-496, miR-497, miR-498, miR-499, miR-500, miR-501, miR-502, miR-503, miR-504, miR-505, miR-506, miR-507, miR-508, miR-509, miR-510, miR-511, miR-512-3p, miR-512-5p, miR-513, miR-514, miR-515-3p, miR-515-5p, miR-516-3p, miR-516-5p, miR-517*, miR-517a, miR-517b, miR-517c, miR-518a, miR-518a-2*, miR-518b, miR-518c, miR-518c*, miR-518d, miR-518e, miR-518f, miR-518f*, miR-519a, miR-519b, miR-519c, miR-519d, miR-519e, miR-519e*, miR-520a, miR-520a*, miR-520b, miR-520c, miR-520d, miR-520d*, miR-520e, miR-520f, miR-520g, miR-520h, miR-521, miR-522, miR-523, miR-524, miR-524*, miR-525, miR-525*, miR-526a, miR-526b, miR-526b*, miR-526c, miR-527, miR-532, miR-542-3p, miR-542-5p, miR-544, miR-545, miR-548a, miR-548b, miR-548c, miR-548d, miR-549, miR-550, miR-551a, miR-552, miR-553, miR-554, miR-555, miR-556, miR-557, miR-558, miR-559, miR-560, miR-561, miR-562, miR-563, miR-564, miR-565, miR-566, miR-567, miR-568, miR-569, miR-570, miR-571, miR-572, miR-573, miR-574, miR-575, miR-576, miR-577, miR-578, miR-579, miR-580, miR-581, miR-582, miR-583, miR-584, miR-585, miR-586, miR-587, miR-588, miR-589, miR-590, miR-591, miR-592, miR-593, miR-594, miR-595, miR-596, miR-597, miR-598, miR-599, miR-600, miR-601, miR-602, miR-603, miR-604, miR-605, miR-606, miR-607, miR-608, miR-609, miR-610, miR-611, miR-612, miR-613, miR-614, miR-615, miR-616, miR-617, miR-618, miR-619, miR-620, miR-621, miR-622, miR-623, miR-624, miR-625, miR-626, miR-627, miR-628, miR-629, miR-630, miR-631, miR-632, miR-633, miR-634, miR-635, miR-636, miR-637, miR-638, miR-639, miR-640, miR-641, miR-642, miR-643, miR-644, miR-645, miR-646, miR-647, miR-648, miR-649, miR-650, miR-651, miR-652, miR-653, miR-654, miR-655, miR-656, miR-657, miR-658, miR-659, miR-660, miR-661, miR-662, miR-663, miR-7, miR-9, miR-9*, miR-92, miR-93, miR-95, miR-96, miR-98, miR-99a and miR-99b in various clinical diseases (including a variety of tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system); Biochips of serum/plasma microRNAs are prepared to determine the changes of serum/plasma microRNAs in different diseases, and meanwhile, Solexa sequencing and analysis on microRNAs in serum/plasma in different diseases are conducted.

The research and development of a technology for detecting disease-related serum/plasma microRNAs. Specifically, the microRNAs with disease-related specificity changes are screened out, their primers are collected into a PCR kit (RT-PCR or Real-time PCR) to prepare a disease-diagnostic kit, or their reverse complementary sequences are dripped on chips as probes so as to prepare the biochips for detecting serum/plasma microRNAs specific for a certain disease.

Presently, the technologies of traditional biochemistry and molecular biology for the clinical diagnosis of diseases are relatively complicated and insensitive. Novel techniques developed in recent years possibly useful for disease diagnosis are gene chip technique, protein (antibody) chip technique, etc. The changes at mRNA level measured through gene chips cannot completely reflect the actual changes at protein level, since the bioactivity of protein is closely related to post-transcriptional modification such as glycosylation and phosphorylation. In addition, for detection of many diseases, marker molecules in body fluids and blood cannot be detected through gene chip technology. Meanwhile, protein (antibody) chip technique and proteomic techniques also bear their limitations. In human body, especially in serum/plasma, there are tens of thousands of protein and polypeptide segments with extensively distributed concentrations, and the number of proteins definitely reported is very small, let alone those quantified. It is an extremely arduous task to find out those proteins having close relation with specific diseases from the large quantity of proteins and understand their roles in histopathologic changes. Moreover, lacking of complete antibody resources is the bottleneck restraining the development of antibody biochip technology. The detection technology for serum/plasma microRNAs based on biochips of serum/plasma microRNAs and diagnostic kits skillfully combines the peculiar properties of serum/plasma microRNAs with conventional molecular biology detection technique together, which can rapidly analyze the respective constitution of serum/plasma microRNAs in respect of various diseases with high throughput and hence be of extremely clinical practicality. Since the changes of physiological conditions in organs and tissues will cause the constitutional changes of serum/plasma microRNAs, serum/plasma microRNAs can be used as “fingerprints for diseases” to realize early diagnosis of diseases.

The advantages of the technology of detecting serum/plasma microRNAs are as follows:

(1) As novel disease markers, serum/plasma microRNAs possess certain advantages such as extensive spectrum for detection, high sensitivity, low cost for detection, convenient sampling, easy preservation for samples (preserving serum/plasma at −20° C. will do), etc. This method can be widely used in general survey of diseases and other relevant tasks and has become an efficient means for early diagnosis of diseases.

(2) As novel disease markers, serum/plasma microRNAs will improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, and notably increase the clinical detection rate of diseases so as to realize early diagnosis of diseases.

(3) The advantages of the technology of detecting serum/plasma microRNAs lie in that what to be detected is series of disease related markers, thus it can address the differences (i.e., age, sex, race, diet, circumstance, etc.) between individual patients, which are exactly a primary problem difficult to overcome by single disease markers.

In summary, utilizing the technology of detecting serum/plasma microRNAs can confirm diagnosis of histopathologic changes in early stage. These novel serum/plasma markers not only provide material foundation for people to comprehensively understand the mechanism of histopathologic changes in molecule level, but also accelerate the progress in diagnostics and therapeutics of clinical diseases. Of course, a majority of molecular diagnostic techniques used for disease detection in early period are at initial experimental stage and their validity needs to be further verified and improved. Moreover, since every disease has the characteristics of its own, this requires a peculiar method for the detection of said disease. In this manner, it is impossible for all diseases to be detected out only through one or only a few of detection methods. Nevertheless, based on the superiority of serum/plasma microRNAs, it is believed that, in the near future, the diagnostic technique of serum/plasma microRNAs for severe diseases such as cancer will become part of routine physical examination. In addition, microRNA related gene therapy will be widely utilized. Consequently, the overcoming of these diseases will come true, not just a dream.

BRIEF DESCRIPTION OF THE DRAWINGS

The following are the detailed description of the embodiments of this invention with reference to the drawings, wherein:

FIG. 1 shows the RT-PCR result of partial microRNAs directly detected in the serum of a normal person.

FIG. 2 shows the RT-PCR results of the microRNAs in the RNA extracted from the serum of a normal person.

In FIG. 1 and FIG. 2, U6 is a snRNA with a molecular weight of 100 bp, serving as an internal reference molecule in microRNAs experiments. The rest of 12 microRNAs are each miR-181a(181a), miR-181b(181b), miR-223(223), miR-142-3p(142-3p), miR-142-5p(142-5p), miR-150(150) with blood cell specificity; miR-1(1), miR-133a(133a), miR-206(206) from cardiac muscles and skeletal muscles; miR-9(9), miR-124a(124a) from brain tissues; and miR-122a (122a) from liver.

FIG. 3 shows the RT-PCR results of partial micro-RNAs directly detected in the serum of mouse, rat, fetal bovine, calf and horse respectively.

FIG. 4 shows the variable quantity of the partial microRNAs in the serum of a patient suffering from the shown diseases compared with microRNAs in the serum of a normal person.

FIG. 5 shows the ratio between the quantities of macroRNAs and microRNAs in blood cells and serum.

FIG. 6 shows the enzyme digested results of macroRNAs and microRNAs.

THE BEST MODE FOR CARRYING OUT THE INVENTION Example 1 The RT-PCR Experiments of microRNAs in Serum/Plasma

By using RT-PCR technique, it is found and proved that there stably exist various microRNAs in serum/plasma of both human beings and animals, and that their expression levels are considerably high. The specific RT-PCR steps are as follows:

(1) collecting serum/plasma of mice, rats, normal persons and some patients;

(2) preparing samples of cDNA. This operation has two options: one is to directly conduct reverse transcription reaction using 10 μl of serum/plasma; the other is to firstly extract the total RNA from serum/plasma (usually, about 10 μg of RNA can be enriched from 10 ml of serum/plasma) with Trizol reagent (Invitrogen Co.), subsequently obtain cDNA through RNA reverse transcription reaction. The reaction system of reverse transcription includes 4 μl 5×AMV buffer, 2 μl 10 mM each dNTP mixture (Takara Co.), 0.5 μl RNase Inhibitor (Takara Co.), 2 μl AMV (Takara Co.) and 1.5 μl gene specific reverse primers mixtures. The reaction steps successively include 15 minutes of incubation at 16, 1 hour of reaction at 42 and 5 minutes of incubation at 85;

(3) PCR and Electrophoresis observation. The cDNA is diluted by 1/50. To 1 μl diluted cDNA are added 0.3 μl Taq polymerase (Takara Co.), 0.2 μl 10 μM forward primer, 0.2 μl 10 μM universal reverse primer, 1.2 μl 25 mM MgCl₂, 1.6 μl 2.5 mM each dNTP mixture (Takara Co.), 20 μl 10×PCR buffer, 13.5 μl H₂O, and PCR reaction is conducted in the 20 μl system. The PCR reaction is done under the following conditions: one cycle at 95 for 5 mins followed by 40 cycles at 95 for 15 seconds and 60 for 1 minute. 10 μl PCR product is subjected to 3% Agarose Gel Electrophoresis, which is observed under ultraviolet lamp after EB staining.

The detailed experimental results are shown in FIG. 1. FIG. 1 shows the experimental results of RT-PCR directly conducted on the serum of normal persons. The all over 500 mature microRNAs in human being are selected for conducting RT-PCR reaction, of which 12 microRNAs are shown in FIG. 1 and each miR-181a, miR-181b, miR-223, miR-142-3p, miR-142-5p, miR-150 with blood cell specificity; miR-1, miR-133a, miR-206 from cardiac muscles and skeletal muscles; miR-9 and miR-124a from brain tissues; and miR-122a from liver. It can be seen from the results that all microRNAs from the above-mentioned four tissues are detectable in blood, and that not all over 500 mature microRNAs have high expression level in the serum/plasma, with some microRNAs being in fairly trace amount and even being normally nondetectable.

To further verify that there stably exist the microRNAs in serum/plasma, RNA is firstly extracted from the serum of normal persons, then all over 500 mature microRNAs of human are selected for PCR experiment. As shown in FIG. 2, the results of FIG. 2 is quite consistent with that of FIG. 1, the singleness of the PCR products indicating that both two assays can detect the expression and level of the microRNAs in people's serum/plasma, and proving that there stably exist microRNAs of various tissues sources in people's serum/plasma. In addition, the same method is used to detect the expression and level of over 500 microRNAs in the serum/plasma of mouse, rat, fetal bovine, calf and horse, it is also found that there is stable expression of microRNAs of various tissues sources in serum/plasma of mouse, rat, fetal bovine, calf and horse (see FIG. 3).

Example 2 The Real-Time PCR Experiments of microRNAs in Serum/Plasma

Quantitative PCR experiments of microRNAs in serum/plasma are conducted to study the specific variation of microRNAs quantity in serum/plasma during the course of various diseases, including various tumors, various acute and chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute and chronic infectious diseases caused by various pathogenic microorganisms; other acute and chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular disease, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system. The experimental principles and experimental steps of quantitative PCR are basically the same as those of RT-PCR, with the only difference between them being the addition of a fluorescent dye EVA GREEN in the process of PCR. An ABI Prism 7300 fluorescent quantitative PCR instrument is used to conduct PCR reaction under the following conditions: one cycle at 95° C. for 5 mins followed by 40 cycles at 95° C. for 15 seconds and 60° C. for 1 minute. The data processing method used is ΔΔCT method, wherein CT is the number of cycles when the reaction reaches the threshold. The expression level of each microRNAs relative to that of internal standard reference can be expressed by the equation of 2-ΔCT, wherein ΔCT=CT_(sample)−CT_(internal reference). Reverse transcription reactions are directly conducted on serum/plasma samples of a patient and those of a normal person, and the quantities of microRNAs contained in each sample of serum/plasma are compared through quantitative PCR reactions.

Serum samples of patients who suffer from aplastic anemia, breast cancer, osteosarcoma, CNS (Central Nervous System) lymphoma, diabetes are selected, and at the same time, all over 500 mature microRNAs of human beings are used to conduct PCR reaction experiments. FIG. 4 shows the quantitative PCR experimental results of microRNAs within serum of patients and normal persons which include the above-mentioned miR-181a, miR-181b, miR-223, miR-142-3p, miR-142-5p, miR-150 with blood cell specificity; miR-1, miR-133a, miR-206 from cardiac muscles and skeletal muscles; miR-9, miR-124a from brain tissues; and miR-122a from liver. The ratio of the microRNAs quantity in serum between normal persons and patients suffering from aplastic anemia, breast cancer, osteosarcoma, CNS (Central Nervous System) lymphoma, diabetes are respectively up-regulated or down-regulated, and the variation extent of the microRNAs quantity from the same tissue source differs in patients with different diseases, indicating that there is specificity variation of microRNAs quantity in the serum/plasma of patients with different diseases. They can be taken as a type of novel markers for disease diagnosis.

Example 3 The Superiority of Serum/Plasma microRNAs as Disease Markers

Through detecting the quantities of microRNAs and macroRNAs in serum and blood cells, it is found that there is an abundant content of microRNAs in serum. See FIG. 5. As represented by U6 molecules with a molecular weight of 100 bp and ribosomal RNA molecules with molecular weights being 18S and 28S respectively, the quantity of macroRNAs in blood cells is at least tens times that in serum; while the quantity of microRNAs in serum remains the same as that in blood cells except the microRNAs with blood cell specificity. Therefore, serum/plasma will specifically enrich small molecule RNAs, especially microRNAs.

It is also found that microRNAs are to some extent able to resist the action of endonuclease, which is possibly one of the reasons why microRNAs can stably exist in serum/plasma. Total RNAs extracted from cultured cell line are processed with endonuclease RNase A and the remaining quantity of macroRNAs and microRNAs are then detected. As shown in FIG. 6, it is found that microRNAs can to some extent resist the degradation of endonuclease while the macroRNAs are substantially completely cut off. Therefore microRNAs can stably exist in serum/plasma.

Based on the two characteristics of abundance in content and stable existence of microRNAs in serum/plasma, microRNAs could be well applied in clinical test.

Example 4 Preparation of the Biochip of Serum/Plasma microRNAs Useful for Disease Diagnosis

A biochip of serum/plasma microRNAs is fabricated to verify the reliability of a kind of serum/plasma microRNAs probes relating to diseases which are selected through quantitative PCR method. The biochip contains all microRNAs probes that can be normally detected in people's serum/plasma, constituting a probe library. See Table 1.

When the probes are specifically applied in certain disease diagnosis or efficacy screening, some probes of the probe library are put together to construct a probe collection which makes it possible to quantitatively detect the variation of microRNAs in the specific conditions. For example, when diagnosing colon cancer, the collection of probes that have interaction with microRNAs of numbers 17-5p, 21, 103, 106a, 107, 126*, 143, 145, 150, 155 and 210 is used. For another example, when diagnosing myocardial hypertrophy and chronic heart failure, the collection of probes that have interaction with microRNAs of numbers 21, 23a, 23b, 24, 27a, 27b, 125b, 195, 199a, 214, 217, 133a is used. In addition, the chip can also do high-throughput screening of the probes of microRNAs varying stably in serum/plasma, and diseases can be predicted and diagnosed based on the overall variation of microRNAs in serum/plasma.

Sequencing method or quantitative PCR method is firstly used to determine that there is more than one copy of microRNAs in serum/plasma, and then reverse complementary probes of these microRNAs are synthesized, after which these probes are spotted on a chemically-modified slide in a size of 75×25 mm using a biochip microarrayer SmartArray™. The samples spotted on the chip also include U6 and tRNA as internal standard, artificially-prepared external standard in length of 30 bases, Hex as positive control etc. The entire lattice is divided into 4 sub-lattices and each sub-lattice has 23 rows and 21 columns, wherein the spot distance is 185 μm and the spot diameter is about 130 μm and each probe was repeatedly spotted for 3 times.

The operational procedure of the biochip is: (1) extracting the total RNA from serum/plasma and detecting its quality through formaldehyde denaturing gel electrophoresis; (2) separation of microRNAs: 50-100 μg total RNA is taken to separate microRNAs from total RNA with Ambion's miRNA Isolation Kit (Cat #. 1560); (3) fluorescently-labeling of microRNAs samples: microRNAs samples are fluorescently-labeling with T4 RNA ligase, then precipitated with absolute ethanol, and then blown to dryness for chip hybridization; (4) hybridization and cleaning: RNA is dissolved into 164, hybridizing solution (15% formamide, 0.2% SDS, 3×SSC and 50×Denhardt's solution), and hybridized at 42 overnight. After completion of the hybridization, it is washed in a solution containing 0.2% SDS and 2×SSC at about 42 for 4 minutes, and then washed in a solution containing 0.2×SSC at room temperature for 4 minutes. Thereafter, the slides can be used for scanning immediately after being dried; (5) chip scanning: the chip is scanned with two-channel laser scanner LuxScan 10K/A; (6) data extracting and analysis: the chip image is analyzed with an image analyzing software LuxScan 3.0, the image signal is transformed into digital signal, and finally differentially-expressed genes are analyzed and selected with SAM method.

A biochip is prepared as above by using a kind of serum/plasma microRNAs probes which express greatly differently under disease condition and normal physiological condition double-verified by quantitative PCR technique and biochip technique. As compared with the traditional chip, there is no significant improvement in the manufacturing process and operational procedure of this biochip, but this chip simplifies the probe library, thereby greatly reducing the manufacturing cost and production time of the chip, and hence is easy to prepare. Meanwhile it increases the pertinence and practicability of chip. The application of the chip in practice can detect diseases in an early phase with only need of the serum/plasma of a patient and no need of other tissues, which helps guide the diagnosis and treatment.

Example 5 Preparation of Kits of microRNAs Useful for Disease Diagnosis and Prediction

The manufacturing processed and operational procedures of microRNAs kits useful for diagnosis, prediction of complication occurrence and malignant disease relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy, forensic authentication and prohibited drug inspection, etc. of all diseases are based on quantitative PCR technique and semi-quantitative PCR technique and biochip technique. The above-mentioned diseases include various tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system.

Sequencing method or quantitative PCR method is firstly used to determine that there is more than one copy of microRNAs in serum/plasma. Then, a kind of serum/plasma mircoRNAs that have a big difference between the expression levels in disease condition and in normal physiological condition are screened out through the techniques of quantitative PCR and biochip, which are taken as an indicator for predicting whether canceration or other disease occurs and diagnosing the pathological degree. Finally the number of screened corresponding serum/plasma microRNAs of each disease would be controlled to over ten to tens, which is the optimized condensement of the chip-probe library. The kit contains a batch of serum/plasma mircoRNAs primers, Taq polymerase, dNTP, etc. The value of the kit lies in making it possible to detect the changing trend of microRNAs through the most simplified probe library and with only need of serum/plasma and no need of any other tissue samples, and further predict the probability of occurrence of diseases or diagnose the pathological phase of diseases based on this changing trend detected. Thus, the application of this kit in practice can increase the possibility of discovering diseases in an early phase, which helps guide the diagnosis and treatment of diseases. 

1-24. (canceled)
 25. A kit for detecting pancreatic carcinoma which comprise: a container in which a probe for specifically binding to and detection miR-25 is contained; and a specification; wherein the probe is labeled with a detectable label.
 26. The kit of claim 25, wherein the probe is labeled with an isotope.
 27. The kit of claim 25, wherein the probe is labeled with a fluorescent.
 28. The kit of claim 25, wherein the kit further comprises one or more pairs of primers for amplifying micron in human serum/plasma.
 29. The kit of claim 25, wherein the probe is probe-miR-25 probe-miR-25 TCAGACCGAGACAAGTGCAATG (SEQ ID NO.: 132).


30. The kit of claim 25, wherein the kit further comprises reagents for extracting or enriching microRNAs in the serum/plasma sample.
 31. A biochip for detecting pancreatic carcinoma which comprises a substrate on which a probe for specifically binding to and detection miR-25 is fixed.
 32. The biochip of claim 31 wherein the probe is labeled with a detectable label.
 33. The biochip of claim 32 wherein the probe is labeled with an isotope.
 34. The biochip of claim 32 wherein the probe is labeled with a fluorescent.
 35. The biochip of claim 31 wherein the biochip further comprises probes for detecting a micro-RNA selected from the group consisting of: miR-20a, miR-21, miR-24, miR-99, miR-185, and miR-191.
 36. A method for detection tumor wherein the tumor is pancreatic carcinoma and the method comprises: (a) providing a serum or plasma sample of a subject; (b) detecting presence and amount of miR-25 in the serum or plasma sample by using a pair of primer and/or a probe to obtain a measurement value V1, wherein the primer and/or probe are labeled with a detectable label; and (c) comparing the measure value V1 with the standard valve V0, wherein the measure value V1 is significantly high means that the subject is more susceptible for or suffers from pancreatic carcinoma.
 37. The method of claim 36, wherein the probe is labeled with an isotope.
 38. The method of claim 36, wherein the probe is labeled with a fluorescent.
 39. The method of claim 36 wherein the probe is probe-miR-25 probe-miR-25 TCAGACCGAGACAAGTGCAATG  (SEQ ID NO.: 132).


40. The method of claim 36, wherein the subject is human.
 41. The method of claim 36, wherein the sample is a serum sample. 